Compare Merck & Co., Inc. (MRK) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NVR Inc. Common Stock — how do they compare? Merck & Co., Inc. trades at $149.17 (market cap $350.29B), while NVR Inc. Common Stock trades at $5,750 (market cap $15.45B). The key difference: Merck & Co., Inc. is far larger — about 22.7× NVR Inc. Common Stock's market cap, and Merck & Co., Inc. pays a 2.39% dividend while NVR Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NVR Inc. Common Stock for 0 Days on average.
| MRK | NVR | |
|---|---|---|
Market Cap | $350.29B | $15.45B |
Volume | 8,158,912 | 53,419 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $8.10K |
52-Week Low | $82.49 | $5.56K |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $15.36B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $147.37, up 1.32% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals highlight growth momentum. Revenue reached $65.01 billion in 2025, with net income at $18.25 billion, though the P/E ratio of 113.58 reflects high valuation expectations.
Outlook is positive with a consensus price target of $158.50, but risks include patent expirations, regulatory scrutiny, and integration challenges from acquisitions. The stock's premium valuation requires sustained earnings growth to justify further upside, with investor sentiment bolstered by analyst support and strategic pipeline expansion.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
